Journey Medical Corp Announces New Journey with the Experts Video Featuring Karan Lal, DO

SCOTTSDALE, Ariz. - May 10, 2024 - PRLog -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical") today released a new Journey with the Experts video featuring Karan Lal, DO, a double board-certified pediatric and cosmetic dermatologist with Affiliated Dermatology in Scottsdale, Arizona. Dr. Lal sits down with Journey Medical to discuss keloids, including what they are, why they occur, and how those affected can seek treatment from their local dermatology practice.

According to the American Academy of Dermatology, a keloid is a scar that may form after an injury to the skin, such as a burn or puncture wound; rarely, a keloid can appear on uninjured skin. To view the Journey with the Experts video featuring Dr. Lal, please visit https://vimeo.com/936780689/f6b8be29e5.



About Journey with the Experts

Journey with the Experts is an educational initiative supported by Journey Medical Corporation, the medical dermatology company. The initiative is designed to educate the general public on common medical dermatology skin disorders and explain how these conditions can be treated at local dermatology practices.

The information, including, without limitation, topics, presentations, discussions, content, descriptions or any other material contained herein is for informational purposes only. None of the material herein is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified HCP with any questions you may have regarding a medical condition or treatment and before undertaking a new healthcare regimen. Never disregard professional medical advice or delay seeking it because of something you have heard, observed, or inferred herein. Any reliance is strictly prohibited.

About Journey Medical Corporation

Journey Medical is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA -approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology's most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (NASDAQ:FBIO). Journey Medical's common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission ("SEC"). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

About Karan Lal, DO

Originally from New York City, Dr. Lal grew up in Queens and attended Hunter Science High School in Manhattan. He graduated summa cum laude from the New York Institute of Technology, where he completed a rigorous seven-year accelerated combined medical program. He was selected to be an academic medical scholar, during which he received a Master of Science in neuroscience and a scholarship for three years of medical school and graduate training. He was elected to the Sigma Sigma Phi and Psi Sigma Alpha medical honor societies.

He completed his internal medicine internship at the University of Connecticut Medical Center where he was elected intern of the year. He completed a three-year dermatology residency at the University of Massachusetts, where he was elected chief resident. He continued at the University of Massachusetts to complete a pediatric dermatology fellowship, where he gained an interest in vascular anomalies, pediatric laser, and dermatologic surgery of pediatric patients. Dr. Lal specializes in pediatric and adult dermatology, laser surgery, soft tissue filler augmentation, body sculpting, melanocyte keratinocyte transplant surgery for vitiligo and hypopigmentation, pigmentary abnormalities of the skin and enjoys treating patients from birth onwards. He is an expert in atopic dermatitis, vitiligo, melasma, psoriasis, and hidradenitis and has worked in specialty clinics among experts. He is the only board-certified pediatric and fellowship-trained cosmetic dermatologist in the United States.

Dr. Lal is often featured in the media and has been quoted in ELLE, Harper's Bazaar, Cosmopolitan, Huffington Post, Romper, NBC news, and Marie Claire. He is currently a member of the DEI work group for the American Society of Dermatologic Surgery and has a passion for treating the medical and cosmetic needs of patients from all different backgrounds. For additional information about Dr. Lal, please visit https://affderm.com/our-providers/.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words "the Company", "we", "us" and "our" may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words "anticipate," "believe," "estimate," "may," "expect," "will," "could," "project," "intend," "potential" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third- party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products' commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful development and regulatory approval of the DFD-29 product candidate and any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties' cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.